ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

244
Analysis
Health Care • India
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
•19 Feb 2025 21:14•Broker

Top Conviction Ideas - “Pharmaceutical & Hospitals”

The pharmaceutical universe under our coverage reported Q3FY25 growth of 10.2% YoY and 2.3% QoQ, driven by strong growth in the India business...

Logo
372 Views
Share
•14 Feb 2025 02:44•Broker

HSIE Results Daily: Siemens, Lupin, Ashok Leyland, Bharat Forge, Steel Authority of India

Siemens: Siemens India Ltd (SIL) delivered standalone (including energy business) Q1FY25 revenue/EBITDA/APAT of INR 45/5.6/4.9bn, a miss/beat to...

Logo
299 Views
Share
•04 Feb 2025 06:45•Broker

Axis Top Picks for the month of February 2025

Axis Top Picks Basket delivered excellent returns of 12% in the last year against an 8.2% return posted by Nifty 50 over the same period, beating...

Logo
363 Views
Share
•15 Jan 2025 21:37•Broker

Pharma and Healthcare (Q3FY25E): Growth Momentum, Margin Visibility Stay Intact

The India Pharma & Healthcare sector is expected to see steady growth in Q3FY25E. We project sales/EBITDA growth of 11%/13% YoY for our coverage...

Logo
327 Views
Share
•09 Jan 2025 22:56•Broker

Q3FY25 - Consolidated Earnings Preview

The Q3FY25 earnings season was marked by a) Festival demand, 2) Sequential improvement in government spending, 3) Moderation in Urban consumption

Logo
328 Views
Share
x